Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Down 2.6% – What’s Next?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares traded down 2.6% during trading on Tuesday . The stock traded as low as $37.93 and last traded at $38.12. 114,650 shares were traded during trading, a decline of 72% from the average session volume of 414,313 shares. The stock had previously closed at $39.12.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AMPH shares. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $60.33.

Amphastar Pharmaceuticals Price Performance

The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a fifty day simple moving average of $46.04 and a two-hundred day simple moving average of $44.54. The company has a market cap of $1.84 billion, a PE ratio of 12.76, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the transaction, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,533 shares of company stock worth $1,987,482 over the last three months. 27.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after buying an additional 398 shares in the last quarter. Asset Management One Co. Ltd. acquired a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at about $78,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.